Ophthalmology

Data suggest eyes with a higher ratio of drops taken versus prescribed were significantly more likely to achieve target IOP at 6 months or 1 year.

No advantage was associated with blue light-filtering IOLs in terms of risk of all-cause or traffic-related injury and comfort with driving.

Data suggest most patients who receive a new diagnosis of PACG in the United States do not have a prior diagnosis of anatomical narrow angle.

Significant rapid improvement were observed in both signs and symptoms of thyroid eye disease at week 6 after 2 infusions of 10mg/kg VRDN-001.

Functional and anatomical improvements with aflibercept treatment were obtained at week 24 and persisted until week 52.

Data show foveal thickness fluctuation was significantly associated with logMAR BCVA and the defect length of the foveal EZ band.

Both a higher self-reported water intake and a greater measured 24-h urine volume were tied to an increased DED prevalence.

However, 82% of patients with proliferative diabetic retinopathy at year 2 of the RECOVERY trial demonstrated an improvement in DRSS levels from baseline.

President and CSO of Odylia Therapeutics discusses the gene therapy pipeline, research and differences in operating as a nonprofit biotech company.

Dr Peter Kaiser shares helpful hints for patient communication and for including biosimilars in clinical practice.

An ophthalmologist discusses challenges and concerns that physicians might face when using biosimilars for retinal diseases.

Cross-sectional data suggest a discontinuity in endothelial cell–density measurements just below 2500 cells.

Dr Peter Kaiser provides an overview of biosimilars that are either approved or are being developed for treatment of retinal diseases.

Dr Kaiser shares critical differences in primary outcome readout in clinical studies for biosimilars vs reference products for retinal diseases.

Dr Peter Kaiser outlines approval process of biosimilars and highlights key differences from approval process of reference products.

An ophthalmology expert provides an overview of biosimilars and their potential in ophthalmology practices.

The worldwide burden of vision loss continues to climb, but there may be solutions with regards to better access to care and improved screening.

Machine learning algorithms successfully predicted visual and anatomic outcomes and dosing frequency in patients with macular edema secondary to CRVO.

Data show 77% of eyes with DME in the IRIS Registry received only one type of anti-VEGF agent over an average follow-up of 2.3 years.

The NDA was granted Priority Review designation with a PDUFA target action date of November 26, 2022.

The port delivery system provides good visual outcomes for patients with nAMD despite presence of fluid in post-hoc analysis of Archway trial.

A post-hoc analysis of the GATHER1 trial suggests avacincaptad pegol reduced GA lesion growth across all distances from the foveal center point, when compared to sham.

Longer time to intravitreal aflibercept injection (>3 months) showed less visual improvement versus shorter time (<1 month).

Overall 70% of the patients in both PDS with ranibizumab and ranibizumab alone had almost no retinal thickness fluctuations.

Evidence of pegcetacoplan treatment effect observed in the distribution of patients across quartiles in both OAKS and DERBY.

Monthly or every other month intravitreal pegcetacoplan reported to be tolerated in DERBY and OAKS trials.

An assessment of anti-VEGF dose regimen strategies concludes with little difference in outcomes among treatment arms at 2 years.

Over a 40-year follow-up, approximately one-quarter of the study cohort with juvenile arthritis were reported to have active uveitis.

Nonmetropolitan counties have a lower density of ophthalmologists compared to metropolitan counties.

A faster rate and central location of GCC thinning was associated with lower vision-related quality of life.